title: [Diabetes mellitus in elderly: geroprotective and antidiabetic properties of delta-sleep induced peptide].
abstract: Delta-sleep induced peptide (DSIP) has a wide range of positive regulator properties. It is known as antioxidant, immunomodulator, antistressor and other, that important as for diabetes, and for aging mechanisms. Aim of the study was to investigate effects of treatment by DSIP-containing drug "Deltaran" in elderly diabetic patients.
  
  
  METHODS
  As the pilot study we examined 11 elderly diabetic patients (mean age 66.3 yr, BMI--28.5 kg/m2, duration of diabetes 12.5 yr). All patients receive 20 doses of DSIP-containing drug "Deltaran" daily. Tests was before and after 60 days after beginning treatment. Blood samples took before and after 60 minutes after standard carbohydrates breakfast.
  
  
  RESULTS
  After treatment were observed improvement of the parameters of quality of life on SCAG scale as the impairment of recent memory (p=0.003), mood depression (p=0.019), emotional lability (p=0.002) and anxiety (p=0.000). Also were observed improvement of quality of sleep and felling between meals in treating patients (p=0.010). Another positive tendencies consist of decrease of BP (ns), increase of ABI (ns), increase of pallestesia (p=0.017), decrease of MAU frequency (p=0.011) and decrease of glycaemia levels after load (p=0.033). And also after treatment were observed decrease of basal and reactive levels in blood of growth hormone (p=0.034 and p=0.005 accord.), insulin (ns), cortisol (ns) and on the contrary increase of dehydroepiandrosterone sulfate levels (ns). Main positive change observed in patients received only diabetic diet, where was a decrease of insulin resistance and in patients with latent autoimmune diabetes (type LADA), where was a increase insulin secretion and decrease of daily dose of insulin requiring.
  
  
  CONCLUSIONS
  The pilot trial indicate beneficial antidiabetic and geroprotective effects of DSIP-contaning drug "Deltaran" in elderly diabetic patients.
authors.forename: V I
authors.initials: VI
authors.lastname: Odin
authors.forename: T V
authors.initials: TV
authors.lastname: Belikova
authors.forename: E S
authors.initials: ES
authors.lastname: Pushkova
authors.forename: N A
authors.initials: NA
authors.lastname: Barr
mesh_terms: D000281:Administration, Intranasal; D000368:Aged; D000375:Aging / Q000097:blood / Q000187:drug effects* / Q000378:metabolism; D003701:Delta Sleep-Inducing Peptide / Q000008:administration & dosage / Q000627:therapeutic use*; D003920:Diabetes Mellitus / Q000097:blood / Q000188:drug therapy* / Q000378:metabolism; D005260:Female; D006299:Health Services for the Aged; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D007328:Insulin / Q000097:blood; D007333:Insulin Resistance; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D011788:Quality of Life
chemical_list: D007004:Hypoglycemic Agents; D007328:Insulin; D003701:Delta Sleep-Inducing Peptide